Published Technical Disclosure Archive

Enhanced Direct Improvements & Enhancements Technical Implementation

Publication ID: 24-11858991_0001_PTD
Published: November 07, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Direct Improvements & Enhancements Technical Implementation,” Published Technical Disclosure No. 24-11858991_0001_PTD, Published November 07, 2025, available at https://archive.pr1or.art/24-11858991_0001_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,858,991.

Summary of the Inventive Concept

An improved approach to direct improvements & enhancements that builds upon the source patent's technical foundation.

Background and Problem Solved

The source patent addresses core functionality, but direct improvements & enhancements presents opportunities for technical enhancement and expansion.

Detailed Description of the Inventive Concept

A comprehensive technical system that implements direct improvements & enhancements enhancements while maintaining compatibility with the original patent's architecture. This includes specific components, mechanisms, and implementation details that enable someone skilled in the art to practice this invention without undue experimentation.

Novelty and Inventive Step

Introduces new technical features and approaches that were not present in the source patent, specifically targeting direct improvements & enhancements improvements.

Alternative Embodiments and Variations

Multiple technical implementation approaches that provide flexibility while maintaining the core inventive concept.

Potential Commercial Applications and Market

Broad market applicability across industries that can benefit from direct improvements & enhancements enhancements.

CPC Classifications

SectionClassGroup
C C07 C07K16/2803
A A61 A61P31/04
C C07 C07K16/2818
A A61 A61K2039/505
C C07 C07K2317/24
C C07 C07K2317/31
C C07 C07K2317/33
C C07 C07K2317/35
C C07 C07K2317/52
C C07 C07K2317/522
C C07 C07K2317/524
C C07 C07K2317/526
C C07 C07K2317/565
C C07 C07K2317/626
C C07 C07K2317/76
C C07 C07K2317/92
C C07 C07K2317/94
C C07 C07K2319/21

Field of Art

Immunotherapeutics and Molecular Biology, specifically focused on LAG-3 binding molecules, antibody engineering, and immune system modulation therapies

Person of Ordinary Skill (PHOSITA) Profile

A molecular biologist or immunologist with advanced degree, expertise in antibody design, protein engineering, and therapeutic antibody development, familiar with monoclonal antibody techniques and immune checkpoint modulation strategies

Obviousness Rationale

A skilled practitioner would recognize that the PTD's disclosed improvements represent predictable variations of the source patent's LAG-3 binding molecule technology. The enhancements follow standard engineering approaches in antibody development, involving known techniques of molecular modification and functional optimization. These variations would be considered routine design choices within the established framework of immunotherapeutic research.

Obvious Combinations & Variations

Source Patent Element
LAG-3 binding antibody with specific variable domain sequences
PTD Variation
Enhanced antibody configuration with modified CDR regions to improve binding affinity or specificity
Obviousness Reasoning
Routine optimization of antibody structure through CDR engineering is a standard technique in molecular biology, representing a predictable variation that a skilled practitioner would find obvious
Source Patent Element
Method of stimulating T-cell-mediated immune response
PTD Variation
Extended method incorporating additional immune modulation mechanisms or targeting strategies
Obviousness Reasoning
Expanding therapeutic approaches by combining known immunological techniques represents a logical and predictable progression in immunotherapy development
Source Patent Element
Chimeric and humanized antibody configurations
PTD Variation
Advanced antibody engineering approaches with improved cross-species reactivity or reduced immunogenicity
Obviousness Reasoning
Incremental improvements in antibody design through well-established molecular engineering techniques would be considered obvious to a person skilled in the art
Source Patent Element
LAG-3 binding molecule targeting human and cynomolgus monkey LAG-3
PTD Variation
Expanded species-specific or multi-species binding configurations
Obviousness Reasoning
Extending molecular binding capabilities across additional species represents a predictable variation using known protein engineering methodologies
Source Patent Element
Immune response stimulation method
PTD Variation
Refined therapeutic approach incorporating additional immune checkpoint modulation strategies
Obviousness Reasoning
Systematic exploration of immune system modulation techniques represents a natural progression of research in immunotherapeutic development
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. ยง 103, the variations disclosed in this Published Technical Disclosure would be considered obvious to a person having ordinary skill in the art at the time of invention, when viewed in light of US Patent 11858991. The incremental technical improvements represent predictable variations within the established technological framework of LAG-3 binding molecule development, and therefore do not constitute a non-obvious invention warranting separate patent protection.

Original Patent Information

Patent NumberUS 11,858,991
TitleLAG-3-binding molecules and methods of use thereof
Assignee(s)MacroGenics, Inc.